Isy Goldwasser co-founded Thync to advance a new frontier with breakthrough impact within healthcare and consumer industries. Prior to founding Thync, Mr. Goldwasser was the first employee and a founding member of Symyx Technologies, Inc. (Nasdaq: SMMX) where he served numerous roles including President and then CEO over a period of 16 years - including taking the company public and building the publicly traded business for 10 years. Mr. Goldwasser established a number of large, strategic partnerships with global corporations that totaled more than $500M in revenues. After constructing a successful merger between Symyx and Accelrys (Nasdaq: ACCL), Mr. Goldwasser became an Entrepreneur-in-Residence at Khosla Ventures in 2010. He is a named inventor on more than 40 US, European and Canadian patents and currently serves on the Board of Directors for The Scripps Research Institute and The California Institute for Biomedical Research. Mr. Goldwasser holds a BS degree in Chemical Engineering from MIT and a MS degree in Chemical Engineering from Stanford University.
In 2013 Dr. Pal created the first embodiment of the method used in the Thync bioelectronics platform for the noninvasive modulation of autonomic neural circuits. Since then, Dr. Pal has led the development and testing of Thync’s neuromodulation platform and has been the architect of the algorithms used for stress and anxiety reduction. In 2017 Dr. Pal discovered the link between the use of Thync’s neuromodulation platform and autoimmune disorders. Before Thync, Dr. Pal was at the Molecular and Cellular Biology Department and Center for Brain Science at Harvard where he researched extensively on brain circuit plasticity and function, carbon nanotube arrays for detecting electrical activity in brain tissue, and cortical circuitry involved in sensory information processing. Dr. Pal has a PhD. in Neurobiology from the University of Pittsburgh School of Medicine where he discovered a novel cellular pathway involved in neurodegeneration which has since led to therapies being developed for stroke.
Prior to joining Thync as Chief Software Technology Officer, Anil was Senior VP and Officer of R&D and Support at Accelrys. It was there that he led the company's technology architecture and software development strategy and played an integral role in M&A strategy and integration. Previously, Anil spent 12 years at Oracle serving as a Vice President in their Server Technology organization, Vice President of Service Engineering and Senior Director of Oracle Cloud Services. Anil has also established and led global teams at Auspex Systems and VeriFone.
Dr. Karnik is an industry veteran, having spent over a decade in dermatology development. She was previously the Chief Medical Officer at Suneva Medical, an aesthetics company with devices and pharmaceuticals, and led clinical development at Myoscience, an early stage device company. Dr. Karnik was formerly an entrepreneur-in-residence at Versant Ventures and a management consultant at McKinsey & Company in the healthcare practice. Dr. Karnik has a B.A. from UC Berkeley, an MD from UCSD, and trained as a fellow at UCSF where she held a faculty position.